Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30324356 | 1.00 | SLC5A2 (0.59) | SLC5A2SLC5A1 | |
| SCHEMBL19183410 | 1.00 | SLC5A2 (0.59) | SLC5A2SLC5A1 | |
| SCHEMBL4640886 | 0.94 | SLC5A2 (0.66) | SLC5A2SLC5A1 | |
| SCHEMBL4640899 | 0.94 | SLC5A2 (0.66) | SLC5A2SLC5A1 | |
| SCHEMBL4595400 | 0.92 | SLC5A2 (0.55) | SLC5A2SLC5A1 | |
| SCHEMBL4639844 | 0.91 | SLC5A2 (0.55) | SLC5A2SLC5A1 | |
| SCHEMBL4640420 | 0.91 | SLC5A2 (0.55) | SLC5A2SLC5A1 | |
| SCHEMBL4593802 | 0.91 | SLC5A2 (0.52) | SLC5A2SLC5A1 | |
| SCHEMBL4595647 | 0.91 | SLC5A2 (0.57) | SLC5A2SLC5A1 | |
| SCHEMBL4595282 | 0.91 | SLC5A2 (0.52) | SLC5A2SLC5A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11548906-B2 | Processes for the preparation of SGLT-2 inhibitors, intermediates thereof | EMMENNAR PHARMA PRIVATE LIMITED (IN) | 2023-01-10 | — | — | US | disclosed |
| US-10913762-B2 | Process for the preparation of D-glucitol, 1,5-anhydro-1-C-[4-chloro-3-[[4-[[(3S)-tetrahydro-3-furanyl] oxy]phenyl] methyl] phenyl]-, (1S) and its crystalline forms thereof | MSN LABORATORIES PRIVATE LIMITED (IN) | 2021-02-09 | — | — | US | disclosed |
| US-10913762-B2 | Process for the preparation of D-glucitol, 1,5-anhydro-1-C-[4-chloro-3-[[4-[[(3S)-tetrahydro-3-furanyl] oxy]phenyl] methyl] phenyl]-, (1S) and its crystalline forms thereof | MSN LABORATORIES PRIVATE LIMITED (IN) | 2021-02-09 | — | — | US | disclosed |
| US-20200331946-A1 | PROCESSES FOR THE PREPARATION OF SGLT-2 INHIBITORS, INTERMEDIATES THEREOF | EMMENNAR PHARMA PRIVATE LIMITED, (IN) | 2020-10-22 | — | — | US | disclosed |
| US-20190040094-A1 | PROCESS FOR THE PREPARATION OF D-GLUCITOL, 1,5-ANHYDRO-1-C-[4-CHLORO-3-[[4-[[(3S)-TETRAHYDRO-3-FURANYL] OXY]PHENYL] METHYL] PHENYL]-, (1S) AND ITS CRYSTALLINE FORMS THEREOF | MSN LABORATORIES PRIVATE LIMITED (IN) | 2019-02-07 | — | — | US | disclosed |
| US-20190040094-A1 | PROCESS FOR THE PREPARATION OF D-GLUCITOL, 1,5-ANHYDRO-1-C-[4-CHLORO-3-[[4-[[(3S)-TETRAHYDRO-3-FURANYL] OXY]PHENYL] METHYL] PHENYL]-, (1S) AND ITS CRYSTALLINE FORMS THEREOF | MSN LABORATORIES PRIVATE LIMITED (IN) | 2019-02-07 | — | — | US | disclosed |
| WO-2017130217-A1 | THE PRESENT INVENTION RELATES TO PROCESS FOR THE PREPARATION OF D-GLUCITOL, 1,5- ANHYDRO-1-C-[4-CHLORO-3-[[4-[[(3S)-TETRAHYDRO-3-FURANYL] OXY]PHENYL] METHYL]PHENYL]-, (1S) AND ITS CRYSTALLINE FORMS THEREOF. | MSN LABORATORIES PRIVATE LIMITED (IN) | 2017-08-03 | — | — | WO | disclosed |
| EP-1989191-B1 | GLUCOPYRANOSYL-SUBSTITUTED BENZONITRILE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING SUCH COMPOUNDS, THEIR USE AND PROCESS FOR THEIR MANUFACTURE | BOEHRINGER INGELHEIM INT (DE) | 2011-07-20 | — | — | EP | disclosed |
| US-7745414-B2 | Glucopyranosyl-substituted benzonitrile derivatives, pharmaceutical compositions containing such compounds, their use and process for their manufacture | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-06-29 | — | — | US | disclosed |
| EP-1989191-A1 | GLUCOPYRANOSYL-SUBSTITUTED BENZONITRILE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING SUCH COMPOUNDS, THEIR USE AND PROCESS FOR THEIR MANUFACTURE | Boehringer Ingelheim International GmbH (DE) | 2008-11-12 | — | — | EP | disclosed |
| US-7393836-B2 | D-xylopyranosyl-substituted phenyl derivatives, medicaments containing such compounds, their use and process for their manufacture | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-07-01 | — | — | US | disclosed |
| US-20080058379-A1 | Glucopyranosyl-substituted benzonitrile derivatives, pharmaceutical compositions containing such compounds, their use and process for their manufacture | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-03-06 | — | — | US | disclosed |
| EP-1765842-B1 | D-XYLOPYRANOSYL-SUBSTITUTED PHENYLS, MEDICAMENTS CONTAINING SAID COMPOUNDS, THE USE THEREOF, AND METHODS FOR PRODUCING THE SAME | BOEHRINGER INGELHEIM INT (DE) | 2008-01-09 | — | — | EP | disclosed |
| WO-2007093610-A1 | GLUCOPYRANOSYL-SUBSTITUTED BENZONITRILE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING SUCH COMPOUNDS, THEIR USE AND PROCESS FOR THEIR MANUFACTURE | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-08-23 | — | — | WO | disclosed |
| US-20060009400-A1 | D-xylopyranosyl-substituted phenyl derivatives, medicaments containing such compounds, their use and process for their manufacture | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-01-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080058379-A1 | Glucopyranosyl-substituted benzonitrile derivatives, pharmaceutical compositions containing such compounds, their use and process for their manufacture | UGGT1, GALE, UGT1A4 | SLC5A2 4/4885SLC5A1 5/4885 |
| US-20060009400-A1 | D-xylopyranosyl-substituted phenyl derivatives, medicaments containing such compounds, their use and process for their manufacture | SLC5A1, SLC5A2, SLC2A1 | SLC5A2 2/4885SLC5A1 1/4885 |
| US-20190040094-A1 | PROCESS FOR THE PREPARATION OF D-GLUCITOL, 1,5-ANHYDRO-1-C-[4-CHLORO-3-[[4-[[(3S)-TETRAHYDRO-3-FURANYL] OXY]PHENYL] METHYL] PHENYL]-, (1S) AND ITS CRYSTALLINE FORMS THEREOF | ALG1, FBP1, DAD1 | SLC5A2 98/4885SLC5A1 12/4885 |
| US-11548906-B2 | Processes for the preparation of SGLT-2 inhibitors, intermediates thereof | SLC5A2, SLC5A1, SLC2A4 | SLC5A2 1/4885SLC5A1 2/4885 |
| US-10913762-B2 | Process for the preparation of D-glucitol, 1,5-anhydro-1-C-[4-chloro-3-[[4-[[(3S)-tetrahydro-3-furanyl] oxy]phenyl] methyl] phenyl]-, (1S) and its crystalline forms thereof | ALG1, FBP1, DAD1 | SLC5A2 98/4885SLC5A1 12/4885 |
| US-20200331946-A1 | PROCESSES FOR THE PREPARATION OF SGLT-2 INHIBITORS, INTERMEDIATES THEREOF | SLC5A2, SLC5A1, SLC2A4 | SLC5A2 1/4885SLC5A1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.